Podcasts about cancer detection

Send us Fan MailDogs can detect explosives, narcotics, missing persons, and even disease. But what if their greatest superpower isn't finding things - it's sensing molecular changes inside the human body long before symptoms appear? Today we're exploring whether the canine nose may hold the key to the next generation of cancer diagnostics.Itamar Bitan is the Co-Founder of Dognosis  ( https://www.dognosis.tech/ ), a pioneering company working to unlock one of nature's most extraordinary sensing systems - the canine nose - and combine it with cutting-edge brain-computer interfaces and machine learning.Driven by a passion for both human health and working dogs, Itamar brings together an unusual blend of expertise spanning elite military operations, canine behavior, disease detection, and technology innovation. He spent nearly four years serving in Oketz, the Israeli Defense Forces' elite special operations K9 unit, where he worked as both a combat soldier and commander, developing deep expertise in canine training, scent detection, and high-pressure operational environments.Following his military service, Itamar became the first employee and Head of Operations at Dog-Prognose, a groundbreaking Israeli startup focused on disease-detection dogs, helping advance the use of canine scent detection for medical applications.Today, at Dognosis, Itamar and his team are pursuing an ambitious vision: digitizing canine scent perception itself. By combining the remarkable olfactory abilities of trained dogs with brain-computer interfaces, artificial intelligence, and machine learning, Dognosis aims to create a new generation of diagnostic tools capable of detecting diseases - including cancer - earlier, faster, and potentially more accurately than ever before.Itamar's work raises profound questions about the future of medicine, the untapped biological capabilities of animals, and how technology may help us translate nature's most sophisticated sensing systems into scalable healthcare solutions.#CancerDetection #ArtificialIntelligence #AI #BrainComputerInterface #BCI #CancerResearch #EarlyDetection #Dogs #MedicalInnovation #Biotechnology #FutureOfMedicine #HealthcareInnovation #MachineLearning #PrecisionMedicine #LiquidBiopsy #CanineDetection #CancerScreening #HealthTech #Diagnostics #SciencePodcast #STEM #Innovation #FutureTech #ProgressPotentialPossibilitiesSupport the show

Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr. Davide Soldato discuss JCO article, "Canine Olfaction Combined with Bayesian Modeling for Multi Cancer Detection from Breath Samples, a Phase 2 Study in India" and the innovative breath-based canine olfaction for multi-cancer detection in low-resource settings, the Bayesian modeling integration, and future prospects for scalable, non-invasive cancer screening methods. LINK TO FULL TRANSCRIPT

In this episode, Dr. Rena Malik explores key issues in urologic cancer detection and management with Dr. Scott Eggener. They discuss the importance of regular testicular self-exams, the risks and limitations of full-body screening scans, and evolving innovations in cancer diagnosis and AI in urology. Listeners will gain practical insights on responsible cancer screening, the potential harms of overtesting, and exciting future directions in non-invasive treatment and technology. Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00 Testicular Cancer Detection and Self-Exams 01:18 Risks of Delaying Cancer Treatment 03:12 Kidney Cancer and Incidental Findings 04:22 Why Full-Body Scans Can Cause Harm 06:11 Is There Screening for Kidney Cancer? 07:25 Future of Cancer Detection and AI in Urology Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices

Depending on your media exposure you have likely seen commercials or advertisements for cancer detection tests that look for markers of the disease in your blood. Now a new study examines these tests and determines that they're really not ready … Should you have a commercially advertised cancer detection test? Elizabeth Tracey reports Read More »

This month, a genetic sensor to self-destruct cancer cells, what fish with a gene mutation are revealing about brain blood vessel disease, evidence that hallucinogens like psilocybin put brain cells into a more plastic state to loosen the grip of depression, a new technique to spot the population immunity loopholes that flu might exploit, and why crabs walk sideways... Get the references and the transcripts for this programme from the Naked Scientists website

Colon cancer is the third most common cancer and the second leading cause of cancer death, but the good news is that early detection can save lives.     It often develops slowly over 10–15 years and may show few or no symptoms in the early stages. When detected early, the five-year survival rate is over 90%, and even if it begins to spread, early detection can still improve survival rates to around 70%.     On today's show, I dive into how you can screen for colon cancer easily from home, the best tests to use, and why catching it early is so critical.      I also cover prevention, monitoring, and the key risk factors to watch for. By combining healthy habits with regular at-home testing and periodic colonoscopies, you give yourself the best chance of detecting issues early and staying ahead of disease.     So join me on Cabral Concept 3723 to learn more about early cancer detection tests you can do from home and lifestyle strategies that can help improve your odds of staying healthy.     Enjoy the show! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3723 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Scientists at Oregon Health & Science University’s Knight Cancer Institute are pioneering a new way to study cancer that could lead to faster cancer detection and more targeted treatment. It involves 3D printing cancer cells from a patient and miniature versions of organs like bones and lungs. The healthy tissue and cancer cells are placed together inside a tiny device that’s roughly the size of a thumbdrive. Scientists can then observe in real time how they interact and discover ways to halt the cancer’s spread into the healthy tissue.    Luiz Bertassoni is the director of the institute’s Precision Biofabrication Hub, which he helped launch in 2023, and a professor of oncology at OHSU. Since last year, he and his team have received more than $9 million in funding from the National Institutes of Health to advance the potential of these so-called organ-on-a-chip devices in the fight against cancer. The latest grants target an aggressive form of prostate cancer that spreads to bones and a cancer of the bone that spreads to lungs. Bertassoni joins us to talk about this new technology and the promise he thinks it holds for the roughly 40% of adults in the U.S. who will likely develop cancer at some point in their lives.   

Colon cancer is the third most common cancer and the second leading cause of cancer death, but the good news is that early detection can save lives.     It often develops slowly over 10–15 years and may show few or no symptoms in the early stages. When detected early, the five-year survival rate is over 90%, and even if it begins to spread, early detection can still improve survival rates to around 70%.     On today's show, I dive into how you can screen for colon cancer easily from home, the best tests to use, and why catching it early is so critical.      I also cover prevention, monitoring, and the key risk factors to watch for. By combining healthy habits with regular at-home testing and periodic colonoscopies, you give yourself the best chance of detecting issues early and staying ahead of disease.     So join me on Cabral Concept 3723 to learn more about early cancer detection tests you can do from home and lifestyle strategies that can help improve your odds of staying healthy.     Enjoy the show! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3723 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Dr. Jim Berenson, Founder of the Institute for Myeloma & Bone Cancer Research and the Berenson Cancer Center, describes the Institute's work, which includes maintaining a large biobank of patient samples that support both its own research and that being conducted by external groups. This biobank is being used to develop new blood markers for faster disease diagnosis, to assess treatment efficacy, and to support drug development for multiple myeloma and other cancers. Real-time monitoring of patient symptoms with a mobile app is capturing critical, often-missed patient data and providing evidence of clinical trial success. Jim explains, "Myeloma is a bone marrow-based cancer of a type of white cell called a plasma cell. These cells normally make a type of protein antibody that helps us fend off infections. And what happens in myeloma is that one of these types of cells goes rogue and takes over the bone marrow.  As a result, these patients make lots and lots of only one type of antibody, and that protein becomes our tumor marker. They can get into trouble with their kidneys, their blood counts, their bones, and their immune system because they can become very compromised both by the disease and the treatment. Therefore, patients can develop frequent infections." "It's diagnosed mainly through blood work, bone marrow examination, and radiologic tests. The latter used to be X-rays, but today it is MRI, CT, or PET scans. The bone marrow test usually demonstrates too many plasma cells that are clonal, meaning they are all of one type. So, usually, the bone marrow plasma cells make up only one-half percent. Myeloma patients have no less than 10% and up to 99% plasma cells, and they are all of one type. They all make one antibody because normally one plasma cell makes one antibody, but this is a clone that's grown a lot in the bone marrow. So, because the bone marrow directly releases proteins into the blood, there's a lot of the myeloma cell-produced antibody in the blood and/or the urine of these patients." "We now have nearly 60,000 bone marrow and blood specimens collected over the last 25 years from our patients, and we collect them in a way that's very systematic. So we obtain blood weekly in the first month, and bone marrow when they undergo the procedure. And then after the first month, the blood is drawn and obtained for research and for the Biobank about every month. And this is a huge resource for not only our own research, which has uncovered two new blood biomarkers through the use of these samples. And we are also able to use the Biobank as a resource for other research groups and companies, whether biotech, pharma, or in vitro diagnostics, to see if they can find a new marker. So we send them a sample, and they can use it for their work." #IMBCR #MultipleMyeloma #HematologyOncology #PrecisionMedicine #PatientMonitoring #DigitalHealth #CancerResearch #Biomarkers #PersonalizedTreatment #QualityOfLife #MedicalInnovation IMBCR.org Listen to the podcast here

Dr. Jim Berenson, Founder of the Institute for Myeloma & Bone Cancer Research and the Berenson Cancer Center, describes the Institute's work, which includes maintaining a large biobank of patient samples that support both its own research and that being conducted by external groups. This biobank is being used to develop new blood markers for faster disease diagnosis, to assess treatment efficacy, and to support drug development for multiple myeloma and other cancers. Real-time monitoring of patient symptoms with a mobile app is capturing critical, often-missed patient data and providing evidence of clinical trial success. Jim explains, "Myeloma is a bone marrow-based cancer of a type of white cell called a plasma cell. These cells normally make a type of protein antibody that helps us fend off infections. And what happens in myeloma is that one of these types of cells goes rogue and takes over the bone marrow.  As a result, these patients make lots and lots of only one type of antibody, and that protein becomes our tumor marker. They can get into trouble with their kidneys, their blood counts, their bones, and their immune system because they can become very compromised both by the disease and the treatment. Therefore, patients can develop frequent infections." "It's diagnosed mainly through blood work, bone marrow examination, and radiologic tests. The latter used to be X-rays, but today it is MRI, CT, or PET scans. The bone marrow test usually demonstrates too many plasma cells that are clonal, meaning they are all of one type. So, usually, the bone marrow plasma cells make up only one-half percent. Myeloma patients have no less than 10% and up to 99% plasma cells, and they are all of one type. They all make one antibody because normally one plasma cell makes one antibody, but this is a clone that's grown a lot in the bone marrow. So, because the bone marrow directly releases proteins into the blood, there's a lot of the myeloma cell-produced antibody in the blood and/or the urine of these patients." "We now have nearly 60,000 bone marrow and blood specimens collected over the last 25 years from our patients, and we collect them in a way that's very systematic. So we obtain blood weekly in the first month, and bone marrow when they undergo the procedure. And then after the first month, the blood is drawn and obtained for research and for the Biobank about every month. And this is a huge resource for not only our own research, which has uncovered two new blood biomarkers through the use of these samples. And we are also able to use the Biobank as a resource for other research groups and companies, whether biotech, pharma, or in vitro diagnostics, to see if they can find a new marker. So we send them a sample, and they can use it for their work." #IMBCR #MultipleMyeloma #HematologyOncology #PrecisionMedicine #PatientMonitoring #DigitalHealth #CancerResearch #Biomarkers #PersonalizedTreatment #QualityOfLife #MedicalInnovation IMBCR.org Download the transcript here

Fixation on Histology: A New Approach to Bladder Cancer Detection Written based on the research article published in the Journal of Histotechnology To Read the Full Blog, Click Here.  

Robotic pets make life easier for patients with dementia; Risks, benefits of “natural” ED formulas; Sorting out those pricey new injectable osteoporosis drugs; Daily multivitamin delays biological aging; Study challenges notion that aging means inevitable decline; Breastfeeding confers weight loss benefits—to moms; Can you avoid a colonoscopy with a new colon cancer blood test? Color blindness may hide warning signs of cancer.

In this episode, Therese Markow and Dr. John Kisiel discuss early cancer detection using liquid biopsies. Dr. Kisiel explains that liquid biopsies detect cancer signals in blood and urine, including tumor cells, fragments, proteins, and DNA. He highlights the FDA's approval of a blood test for colon cancer and the development of multi-cancer early detection tests. Dr. Kisiel notes that false positive and false negative rates vary by test. He emphasizes the potential of liquid biopsies to complement, not replace, standard screening methods and the need for further validation and clinical trials. Key Takeaways: Liquid biopsies have been used in the oncology community to test if cancer is still present, may need additional or more aggressive treatment, or if the cancer has come back. Each test will have its own false positive and false negative rate, partially based on where manufacturers set the thresholds for that positive/negative result. Peripheral blood-based tests for colon cancer do not detect polyps, and it's the finding and removing of polyps that actually offers the greatest preventive benefit, so that somebody never gets cancer in the first place.    "Another word of cautious optimism, I think that I, personally, and many other people active in the space really view these as an addition to standard of care cancer screening and not a replacement." —  Dr. John Kisiel   Connect with Dr. John Kisiel: Professional Bio: https://www.mayo.edu/research/faculty/kisiel-john-b-m-d/bio-00092659    Connect with Therese: Website:  www.criticallyspeaking.net Bluesky: @CriticallySpeaking.bsky.social Instagram: @criticallyspeakingpodcast Email: theresemarkow@criticallyspeaking.net   Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it. 

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recognize barriers to achieving lung cancer screening for eligible patients; Identify patients at high risk of lung cancer who are eligible for screening; and Outline practical, patient-centered strategies to appropriately integrate lung cancer screening into routine practice.

Prostate MRI is changing how clinicians decide when a biopsy is needed and how sampling is targeted to better detect clinically significant prostate cancer. In this episode of Better Edge, Hiten Patel, MD, discusses MRI‑informed risk stratification, including the use of an MRI‑based risk calculator, and how MRI‑targeted biopsy can reduce missed high‑grade disease. The episode also highlights how PSA density informs decision‑making after a negative MRI and how to manage discordant targeted and systematic biopsy results. Dr. Patel reviews lesion characteristics, like size and suspicion score, in the context of follow‑up and treatment intensity, along with emerging tools like PSMA PET and AI that may further refine detection and biopsy targeting.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Keith Singer, the founder and executive director of Catch It In Time. Camidge and Singer discussed how Singer's background in broadcasting and cable television has led to a career in promoting cancer awareness. Although Singer initially wanted to be an astronaut, a decline in aerospace engineering jobs during the 1970s and a love for the technical side of high school theater led Singer toward television. He left college early and started his career in Cincinnati, first running a boom microphone and later directing newscasts. Singer explained the career hurdles he faced, noting that they led to opportunities for him to hone his skills and exercise creative freedom. In the mid-1980s, a project involving a new pacemaker sparked Singer's interest in using video for health care education. This fascination led him to co-create an innovative platform that broadcast medical programming for physician continuing medical education. Driven by seeing friends and family struggle with cancer, Singer founded the nonprofit Catch It In Time in 2011. His key communication strategy is that cancer should be the supporting actor, not the lead, allowing stories to appeal to targeted audiences based on their hobbies or professions, with cancer awareness as the secondary message. Catch It In Time is currently developing The User's Guide to Oncology, a software-based program that uses gaming technology to guide patients with lung cancer, providing essential information to help them have better conversations with their care teams. Singer stressed the importance of short video content for garnering views for this type of content. Notably, Catch It In Time recently produced a song titled "Breathe Again" by Lilliana De Los Reyes. "Breathe Again" can be found on all major streaming platforms, and all proceeds are dedicated to cancer awareness and research.

Today on Beating Cancer Daily, Saranne brings a lighthearted and informative perspective to cancer detection. After a listener praises her for making cancer more approachable, Saranne realizes the impact humor can have in the fight against this illness. She recounts her own journey with Stage IV breast cancer and emphasizes the importance of regular cancer screenings, especially for skin cancer. Infusing humor into serious topics, she utilizes a Dr. Seuss-inspired rhyme to remember critical signs of skin anomalies and introduces the ABCDEF mnemonic from the Princeton Longevity Center as a practical self-checking method. "Catchy rhymes can save lives; check for brownish spots, dark black dots, and odd-shaped moles." ~ Saranne Today on Beating Cancer Daily: ·     Emphasize the importance of regular skin checks for early detection of cancer·     Use humor to make self-checking for skin cancer more approachable·     Explain a helpful mnemonic (ABCDEF) for remembering key signs of skin anomalies·     Share personal experience to illustrate that even those focused on one type of cancer should remain vigilant about others·     Encourage taking photos of any suspicious skin changes for comparison over time·     Highlight the importance of knowing your family history related to skin cancer·     Recommend consulting with healthcare providers when any changes are noticed·     Remind listeners to help each other with skin checks, especially in hard-to-see areas Resources Mentioned: Princeton Longevity Centerhttps://princetonlongevitycenter.com/ EWG Sunscreen Guidehttps://www.ewg.org/sunscreen/2025 People's Choice Podcast Awards Finalist Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries across 7 continents and features over 390 original daily episodes hosted by Stage IV survivor  Saranne Rothberg.   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne 

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH Blood-based colorectal cancer screening is entering a new era with FDA-approved and emerging tests like Shield and Simple Screen. Alongside updated stool-based options such as Cologuard Plus and CRC-PREVENT, clinicians now have a broader landscape of noninvasive tools to consider and discuss with their patients. Joining Dr. Peter Buch to talk about current recommendations and potential future directions for colorectal cancer screening is Dr. Aasma Shaukat. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine and a Professor of Population Health at NYU Grossman School of Medicine, as well as the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU Langone Health. She's also a co-author of a recent review on blood tests for colorectal cancer.

In this episode of The Top Line, Fierce’s Chris Hayden speaks with Foresight Diagnostics co-founders Dr. Jake Chabon and Dr. Max Diehn about how their company is delivering the next generation of minimal residual disease (MRD) detection in cancer care. Born from research at Stanford University, Foresight’s PhasED-Seq technology delivers ultra-sensitive detection—down to parts per ten million—enabling clinicians to identify microscopic traces of cancer that traditional imaging misses. The discussion explores how Foresight’s MRD platform, CLARITY, can have the ability to support more confident decision-making, from determining curative success in early-stage cancers to guiding consolidation treatment in lymphoma. Chabon and Diehn highlight the company’s biopharma collaborations, clinical trial integration, and evidence-driven approach to guideline inclusion. They also look ahead to a future where MRD testing becomes central to oncology surveillance, accelerating therapy approvals and complementing genomic and digital pathology tools to advance precision medicine.See omnystudio.com/listener for privacy information.

Biochemist Lingyin Li survived breast cancer at just 30 and now works to harness the human immune system to fight cancers that have long evaded treatment. T cells, she says, are powerful cancer killers, but they can be oblivious. She and her lab colleagues have discovered a masking enzyme that squelches the immune system's “danger signals” and are now developing drugs to block that enzyme. She likens her work to an arms race between cancer and immunotherapy. “The cancers are not getting smarter, but we are,” Li tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Lingyin LiConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Lingyin Li, a professor of biochemistry at Stanford University.(00:03:38) Research MotivationLingyin explains how her breast cancer diagnosis inspired her research.(00:04:31) How T-Cells WorkT-cell mechanisms and why they struggle to reach solid tumors.(00:05:38) Immune System OverviewInnate and adaptive immunity and how mutations make cancer recognizable.(00:07:28) Awakening the Immune SystemEfforts to stimulate innate immune cells to detect and expose tumors.(00:10:54) The Cancer SignalDiscovery of cancer-derived DNA signals that alert the immune system.(00:13:01) Cancer's Evasion MechanismHow tumors destroy immune signals to hide from detection.(00:14:26) ENPP1 EnzymeIdentification of ENPP1 as the enzyme enabling immune evasion.(00:15:22) Balancing Immunity and SafetyRole of ENPP1 in autoimmunity and the challenge of targeting it safely.(00:19:30) ENPP1 InhibitorsDevelopment of molecules to block ENPP1 and enhance immune signaling.(00:24:55) Preclinical FindingsThe promising results against aggressive solid tumors in animal studies(00:28:05) From Lab to ClinicThe progress toward FDA approval and preparation for human testing.(00:31:04) Future In a MinuteRapid-fire Q&A: innovation, collaboration, and the outlook for cancer treatment.(00:33:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Tomasz Beer, MD, chief medical officer at Exact Sciences, joins HealthLeaders for a discussion on the clinical research behind Cancerguard tests and how they enable health systems to detect multiple deadly cancers early, streamline diagnostic workflows, and deliver proactive, value-based care. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice. The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

This Veterans Day, we're shining a light on care for those who've served.Dr. Elizabeth (Betsy) O'Donnell, Director of the Multi-Cancer Early Detection Clinic at Dana-Farber Cancer Institute, joins the PQI Podcast to discuss the Sentinel Study—a Department of Defense–sponsored clinical trial offering multi-cancer early detection (MCED) testing to U.S. veterans.Through a single blood draw, the test can screen for more than 50 types of cancer, addressing the urgent need for improved screening among veterans, who face a cancer risk nearly 20% higher than the general population.Dr. O'Donnell shares how this innovative study combines science, service, and compassion to bring life-saving research to those who've served—and what it could mean for the future of oncology care.Listen to learn more about:How early detection technology is transforming the future of cancer careWhy veterans face unique cancer risks linked to their serviceWhat makes the Sentinel Study a model for accessible, equitable screeningThe personal motivation that drives Dr. O'Donnell's workFor more information on the Sentinel study or to determine eligibility, visit redcap.link/VeteransScreeningStudy or contact the Sentinel Team at dfciprevention@mgb.org

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

In this episode, we chat with Dr. Renee Goreham, a physicist and nanotechnologist at the University of Newcastle, and passionate science communicator. Renee is an experimental physicist exploring how our breath could hold the key to detecting lung cancer early—by identifying specific proteins as biomarkers. We also delve into her PhD student's exciting research into a new red-light laser diagnostic tool for breast cancer. Along the way, Renee breaks down the basics of cell biology and shares her inspiring, non-linear journey through physics, nanotech, and beyond. A brilliant example of multidisciplinary science in action. Follow Renee on TikTok: @dr_renee_goreham

On this episode of Impact Quantum, we dive into the visionary world of Sanjay Chittore, founder of Quantum AI Global and QLabs, who's on a mission to bring quantum theory out of the realm of science fiction and into real-world applications. Joined by host Frank La Vigne and the wonderfully quantum-curious Candice Gillhoolley, we unravel common myths about quantum computing—like whether you really need a quantum computer to build quantum products—and explore the massive impacts quantum technology is poised to have on everything from healthcare diagnostics to next-generation memory and sensing.Sanjay shares his journey from startup success through the pandemic to his self-driven deep dive into quantum and AI, revealing why he believes the future hinges on the synergy of quantum physics and electronics, rather than the traditional computing and electronics combination. Prepare to have your assumptions challenged as we discuss what makes quantum so secure, so fast, and so revolutionary—plus real-world examples like quantum memory, quantum sensors in healthcare, and the bold dreams that keep this field moving forward.Whether you're a scientist, entrepreneur, or just quantum-curious, this episode offers inspiring insights into how today's breakthroughs could transform industries and everyday life. Buckle up—things are about to get entangled!Time Stamps00:00 Quantum-AI Product Integration Company04:36 "AI Focus Led to Quantum"08:20 Quantum Discovery and Einstein's Doubts10:49 "Futuristic Startups: Embrace Risks"16:04 "Quantum Computers Lack Storage"19:15 "Quantum Sensors: Superior Precision"22:39 "Quantum Sensor for Cancer Detection"24:48 "Quantum Sensors and Cryptography"28:43 "Quantum: Infinite Between Ones, Zeros"31:50 "Unhackable Quantum Qubits Explained"34:52 "Solving Maze Navigation"38:38 "Quantum Efficiency Simplified"43:19 "Supporting PhDs in Industry"45:02 India's First Quantum Cryptography Product47:42 "Classical to Quantum Conversion"53:40 Quantum Revolution: Theory to Reality54:19 "Bailey's Quantum Farewell"

Blind biopsies leave questions unanswered. In this episode of BackTable OBGYN, host Dr. Mark Hoffman welcomes back Dr. Linda Bradley, an expert in obstetrics, gynecology, and hysteroscopy from the Cleveland Clinic, to discuss the benefits and advancements of direct visualized endometrial sampling over traditional blind biopsy techniques. ---This podcast is supported by:Medtronichttps://www.medtronic.com/en-us/healthcare-professionals/specialties/gynecology/product-portfolio.html---SYNPOSISDr. Bradley emphasizes the importance of hysteroscopy for accurate diagnosis and treatment of various gynecological issues, including abnormal uterine bleeding. They explore the limitations of blind biopsies and the advantages of hysteroscopy in detecting focal lesions, avoiding unnecessary hysterectomies, and ensuring patient safety. The discussion also touches on the economic and procedural challenges in adopting hysteroscopy more widely in clinical practice.---TIMESTAMPS00:00 - Introduction 03:30 - The Evolution of Hysteroscopy at Cleveland Clinic04:49 - Challenges and Innovations in Hysteroscopy06:30 - Clinical Insights: Direct Visualized Endometrial Sampling12:03 - Case Studies and Practical Applications15:46 - The Importance of Visual Examination in Gynecology20:03 - Advocating for Hysteroscopy in Medical Practice31:07 - Patient History and Trauma Considerations31:34 - Cancer Detection and Missed Diagnoses32:14 - Challenges with Unscheduled Bleeding32:56 - Case Study: Blood Transfusions and Hysterectomy33:38 - Importance of Hysteroscopy34:43 - Hysteroscopy Techniques and Best Practices37:41 - Ultrasound and SIS (Saline Infusion Sonohysterography) for Imaging38:45 - Post-Operative Care and Follow-Up47:41 - Environmental and Economic Considerations in Healthcare52:51 - Final Thoughts and Patient Advocacy

What if the future of cancer detection was just a simple blood test away? In this episode of the Women in Leadership Talk Podcast, host Vicki Bradley sits down with Susan Tousi, CEO of DELFI Diagnostics, to explore how she's leading the charge in life sciences with groundbreaking approaches to early cancer detection.Susan shares her journey from corporate leadership to startup CEO, the role of AI in advancing healthcare, and the importance of self-belief when taking bold career leaps. She also opens up about work-life balance, resilience, and why having a strong support system can empower women to lead with confidence.Want to deepen your leadership journey?You'll find two FREE mini-courses designed to elevate your leadership skills and a powerful leadership quiz to help you understand how you show up in the world, personally and professionally. Explore now: www.wilempowered.com, www.wilempowered.com/free-mini-course/ 

In this episode, CANCER BUZZ speaks with Bart Daugherty, vice president of clinical technology and systems at Georgetown Cancer Center, Lifepoint Health, about his program's receipt of a 2025 ACCC Innovator Award. Lifepoint's innovation, Transforming Cancer Detection and Treatment with the AI-Driven Healthy Person Program, leverages artificial intelligence (AI) to analyze the health records of all patients who have received care at Lifepoint Health's facilities and identify those who are at risk of developing catastrophic diseases. This initiative, dubbed the Healthy Person Program, has already impacted over 280,000 patients since the deployment of Lifepoint's AI tool and made significant strides in improving population health in its communities.    Bart Daugherty Vice President, Clinical Technology and Systems Lifepoint Health Brentwood, Tennessee    “We've taken a lot of the administrative burden off of [our cancer team] and allowed them to focus on critical patient [cases].”  – Bart Daugherty    This podcast is part of a special series featuring the 2025 ACCC Innovator Award winners. For a deeper dive into this topic and other content that will help your team reimagine how care is delivered at your cancer program or practice, register today for the ACCC 42nd National Oncology Conference, October 15-17 in Denver, Colorado.    Resources:  Cancer Crushing Prevention and Early Detection  ACCC Recognizes National Cancer Prevention and Early Detection Month  Exploring Current Perceptions of Multi-Cancer Early Detection Testing Among Healthcare Providers  [PODCAST] Ep 05: Rural Cancer Care 

A large observational study found small but potentially meaningful differences in cardiovascular safety among sulfonylureas compared to DPP-4 inhibitors in type 2 diabetes, with glipizide showing a statistically higher risk of MACE. A separate study revealed that over half of advanced-stage lung and colorectal cancer cases involved missed diagnostic opportunities, highlighting systemic delays in workups and follow-up. Finally, the EchoNext deep learning model accurately predicted structural heart disease from ECG data alone, outperforming cardiologists and showing potential for scalable, cost-effective screening. These findings underscore the importance of individualized treatment, earlier cancer detection, and AI-enabled cardiac diagnostics.

Early cancer detection doesn't have to mean invasive tests. In this podcast episode, we sit down with Jeff Bousfield, CEO of Nonacus Cancer Diagnostics, to explore how his UK-based company is revolutionizing precision cancer diagnostics with a powerful suite of non-invasive tools. Jeff shares the human story behind the science and why he believes the future of cancer care starts with precision diagnostics tools that are faster, less invasive, and more accessible to patients.

DermaSensor has developed the first FDA-cleared, AI-powered skin cancer detection device specifically designed for primary care physicians. After spending $27 million on R&D over eight years and conducting 15 clinical studies, the company received FDA clearance in January 2024. Using elastic scattering spectroscopy, the device analyzes cellular and subcellular structures in skin tissue—the same characteristics pathologists examine under microscopes—to provide objective skin cancer risk assessments in under 30 seconds. In this episode, CEO Cody Simmons shares the journey from Boston University research lab to commercial deployment across hundreds of medical practices. Topics Discussed: DermaSensor's eight-year development journey from 30-pound research devices to handheld commercial products The FDA clearance process requiring five pre-submission meetings and over 10,000 pages of documentation Strategic decision to target primary care physicians rather than dermatologists based on competitive intelligence Clinical validation showing device accuracy matches in-person dermatologist assessments Commercial launch strategy achieving coverage from major media outlets without a major PR firm Rapid adoption by hundreds of private practices within the first year post-clearance GTM Lessons For B2B Founders: Learn from competitive failures before choosing your market: Cody observed companies spending "literally hundreds of millions of dollars" targeting dermatologists with similar devices, only to see them "commercially immediately fizzled out" within 2-4 years. Dermatologists, being experts, were confident in their existing processes and questioned why they needed additional tools. This competitive intelligence led DermaSensor to target primary care physicians who welcomed objective second opinions. B2B founders should study why similar solutions failed in adjacent markets and identify underserved segments where their value proposition resonates more strongly. Align your commercial strategy with regulatory requirements years in advance: Cody emphasized that you must "align your plan like your commercial plan with your study" and your FDA indication for use, determining "who's actually approved to use the device for what purpose." This planning must happen years before approval since clinical studies are designed around the intended commercial application. B2B founders in regulated industries should work backwards from their go-to-market strategy when designing regulatory pathways, ensuring clinical evidence supports their target market and use cases. FDA clearance itself can be your biggest PR moment: DermaSensor achieved coverage on ABC, NBC, CBS, Fox, Forbes, Reuters, and Time Magazine's Best Inventions list primarily because "the FDA clearance itself was so big" for a first-in-class device addressing "the most common cancer." They worked with only an independent PR consultant, not a major firm. B2B founders should recognize that major regulatory milestones, especially for novel technologies, inherently generate media interest and plan their launch communications accordingly. Prioritize speed and simplicity when displacing manual processes: The device works in "less than 30 seconds" from pickup to result, addressing primary care physicians who previously had to rely on visual assessment with minimal dermatology training (only "two to four hours of training in medical school"). The combination of speed, objectivity, and ease of use made adoption attractive to non-specialists. B2B founders should design solutions that are dramatically faster and more accurate than existing manual processes, especially when targeting users who lack specialized expertise. Private practices adopt faster than health systems but both are essential: Cody noted that "private practices, because they make decisions so quickly" with "one or two doctors that run the practice" were able to rapidly adopt the technology. However, health systems provide validation and scale. The company focused on building "that whole ecosystem" where "health systems using a private practice, using it. Dermatologists are aware of it." B2B founders should sequence their go-to-market to capture quick wins from agile smaller customers while simultaneously pursuing enterprise accounts for long-term growth and market credibility.   //   Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe.  www.GlobalTalent.co   //   Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM 

Which brand of fish oil do you recommend lately?What supplements can help with ankle pain, specifically perineal tendonitis?Aren't doctors opening themselves up to a lawsuit by not using superior methods of cancer detection?Would magnesium help for atrial fibrillation caused by a heart valve replacement? What do you recommend for severe rheumatoid arthritis?How far apart should I eat any dairy from blueberries so as not to inhibit nutrient absorption?

The big C word- Cancer. It's a scary word to hear and nobody wants to receive the news. Unfortunately, 12 million dogs and cats are diagnosed with cancer each year and Moose's March wants to do something about it. From early cancer detection kits to approved products that can help with the fight against cancer, this organization is doing cool things.

This week: Why your gaze can boost running performance, a breakthrough in early cancer detection, the future of dental implants, and how childhood nutrition shapes adult health. Learn More: https://radiohealthjournal.org/run-faster-cancer-detection-high-tech-teeth/ Learn more about your ad choices. Visit megaphone.fm/adchoices

AI-boost for mammograms—a bridge too far? Plastics and heart disease; What does a high CRP mean? Social media marketing of female aphrodisiac dinged with FDA warning; Roundup gets a makeover; Artificial sweeteners may hasten puberty in kids; Plus an encore of our interview with Dr. Jeffrey Bland introducing Himalayan Tartary Buckwheat as a hedge against age-related immune decline.

For years, China's cancer screening and survival rates have trailed behind those of developed nations. But 2025 could change everything. A breakthrough AI system named GRAPE is now helping Chinese hospitals detect stomach cancer earlier—with 20 percent higher accuracy than human doctors. No tubes, no discomfort—just a quick scan. Could this be the start of AI saving millions of lives? On the show: Heyang, Steve Hatherly & Yushan

(3:08) - A Sweet Solution for Safer Diagnosis and TreatmentThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn more about the use cases of human machine integration, where the technology is at today, and what the future holds! Become a founding reader of our newsletter: http://read.thenextbyte.com/ As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.

This week we discussed Iran & Israel War, Quantum Computing, Cancer Detection,Benefit of Shaking Ears, Accountants in Kiev Ukraine and more   #awakening #iran #quantumcomputing   About my Co-Host: Arnold Beekes Innovator, certified coach & trainer and generalist. First 20 years in technology and organizational leadership, then 20 years in psychology and personal leadership (all are crucial for innovation). ============ What we Discussed:   00:00 What we are discussing in this weeks show   01:40 Iran and Israel War 04:45 29 Countries do not Recognise Israel 09:00 Humanoid Robiotics is going to be massive 11:30 The WHO Pandemic Agreement 13:40 Anti Immegrant Protests in Northern Ireland 14:40 How to Stop the Illegal Immegration 16:20 Meta AI New Model and Flying Cars 19:00 Eventually Ai will be able to do all that humans can do   21:35 Larry Elison wants all Governements to share information for Ai 24:20 Quantum Computing 27:10 Prosthetic leg made for friend 31:15 John Hopkins Can detect Cancer 3 years before other methods detect it 33:10 Clean Hydrogen Fuel from Soda Cans 35:10 Dangers of Car Air Freshners 37:40 Benefits of Yoga Nidra 39:40 Benefits of Shaking Ears 43:35 The Benefits of Ginger 45:50 The Dangers of Bovaer 49:20 The attack on the Farmers 50:40 Obeying Orders not good for you 55:50 The Constant Spraying in Lodz, Poland 57:10 The Shield Protecting Children in the UK 58:40 Accountants in Kiev, Ukraine   ==================== How to Contact Arnold Beekes:   https://braingym.fitness/   https://www.linkedin.com/in/arnoldbeekes/ =============== Donations ⁠⁠ https://www.podpage.com/speaking-podcast/support/ ⁠⁠ ------------------ All about Roy / Brain Gym & Virtual Assistants at https://roycoughlan.com/ ------------------

This week we discussed Iran & Israel War, Quantum Computing, Cancer Detection,Benefit of Shaking Ears, Accountants in Kiev Ukraine and more #awakening #iran #quantumcomputing About my Co-Host:Arnold Beekes Innovator, certified coach & trainer and generalist. First 20 years in technology and organizational leadership, then 20 years in psychology and personal leadership (all are crucial for innovation).============What we Discussed: 00:00 What we are discussing in this weeks show 01:40 Iran and Israel War04:45 29 Countries do not Recognise Israel09:00 Humanoid Robiotics is going to be massive11:30 The WHO Pandemic Agreement13:40 Anti Immegrant Protests in Northern Ireland14:40 How to Stop the Illegal Immegration16:20 Meta AI New Model and Flying Cars19:00 Eventually Ai will be able to do all that humans can do 21:35 Larry Elison wants all Governements to share information for Ai24:20 Quantum Computing27:10 Prosthetic leg made for friend 31:15 John Hopkins Can detect Cancer 3 years before other methods detect it33:10 Clean Hydrogen Fuel from Soda Cans35:10 Dangers of Car Air Freshners37:40 Benefits of Yoga Nidra39:40 Benefits of Shaking Ears43:35 The Benefits of Ginger45:50 The Dangers of Bovaer49:20 The attack on the Farmers50:40 Obeying Orders not good for you55:50 The Constant Spraying in Lodz, Poland57:10 The Shield Protecting Children in the UK58:40 Accountants in Kiev, Ukraine ====================How to Contact Arnold Beekes: https://braingym.fitness/ https://www.linkedin.com/in/arnoldbeekes/===============Donations ⁠⁠ https://www.podpage.com/speaking-podcast/support/ ⁠⁠------------------All about Roy / Brain Gym & Virtual Assistants athttps://roycoughlan.com/------------------

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support. What if your blood could reveal the future of your health - years before symptoms ever appear? In this episode of Eye on AI, Craig Smith sits down with Ash Anwar, co-founder of Molecular You, to explore how AI and advanced biomarker analysis are transforming how we detect and prevent disease.  From a real-life case where stage 1 pancreatic cancer was caught early, to the science behind tracking 250+ dynamic biomarkers, Ash breaks down how Molecular You is shifting healthcare from reactive treatment to proactive longevity.  They dive into the limitations of genetic testing, the power of machine learning models trained on clinical data, and how personalized action plans are helping individuals take control of their health in real time.  If you're curious about the intersection of AI, diagnostics, and the future of preventive medicine—this is a conversation you won't want to miss. Stay Updated: Craig Smith on X: https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) How AI Can Predict Disease Before It Happens   (02:02) Meet Ash Anwar: From Scientist to Health Tech Leader   (06:31) What Is Molecular You and How It Works   (09:43) Why Biomarker Tracking Over Time Is a Game-Changer   (15:46) How Molecular You Detected Stage 1 Pancreatic Cancer   (23:15) Biomarkers vs Genetics: What Really Matters   (28:11) The AI Models Behind Early Disease Detection   (32:37) How the Product Works for Clinics and Consumers   (35:05) Who They Compete With and What Makes Them Different   (37:34) Research vs Product: The Cancer Risk Challenge   (43:43) How Often Should You Get Tested?

Is your business ready for the next wave of AI — or about to be eaten by it?In this week's episode of The Leveraging AI Podcast, Isar Meitis breaks down the latest tectonic shifts in the AI landscape. From OpenAI's aggressive move into enterprise applications to self-improving AI models and FDA-approved cancer detection tools, this isn't just another week in tech — it's a glimpse into the near future of business.AI is no longer just evolving — it's learning how to evolve itself. That means faster innovation, deeper disruption, and greater opportunity for those paying attention. So if you're leading a company, making decisions, or just trying to stay ahead — you can't afford to miss this.Recommendation: If you're relying on dashboards and human analysts alone, it's time to consider the AI layer that's changing enterprise strategy across industries.In this session, you'll discover:Why OpenAI's enterprise push is terrifying startups — and possibly Google and MicrosoftHow Databricks and Snowflake are redefining BI with "systems of intelligence"What Mary Meeker's AI mega-report says about tech acceleration — and what's not acceleratingWhich AI model is rewriting its own code (yes, you read that right)How AI just helped the FDA approve a tool for early breast cancer detectionWhy layoffs tied to AI aren't slowing down — and why most leaders are still underestimating the shiftWhat's brewing at Microsoft, Meta, Apple, and Anthropic in the battle for enterprise dominanceHow new AI agents may eliminate the need for ad agencies and call centersAbout Leveraging AI The Ultimate AI Course for Business People: https://multiplai.ai/ai-course/ YouTube Full Episodes: https://www.youtube.com/@Multiplai_AI/ Connect with Isar Meitis: https://www.linkedin.com/in/isarmeitis/ Join our Live Sessions, AI Hangouts and newsletter: https://services.multiplai.ai/events If you've enjoyed or benefited from some of the insights of this episode, leave us a five-star review on your favorite podcast platform, and let us know what you learned, found helpful, or liked most about this show!

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support.   What if AI could predict exactly when you'd get sick—and help you prevent it?   In this episode of Eye on AI, Dr. Eric Topol, world-renowned cardiologist, author, and AI health pioneer, joins us to unveil the future of preventive medicine. We dive deep into the themes of his new book Super Agers, which lays out a groundbreaking blueprint for extending healthspan—not just lifespan—through the power of multimodal AI and deep biological data.   Dr. Topol explains how AI models can now analyze a full-stack of human data—genomics, proteomics, metabolomics, microbiome, and more—to forecast age-related diseases like cancer, Alzheimer's, and heart disease decades before symptoms appear. This isn't science fiction. It's here now.   If you're interested in the intersection of AI, longevity, and the future of medicine, this is a must-listen.   Where AI Works tackles the big questions shaping AI's role in business today, cutting through the hype to deliver actionable insights for leaders. Brought to you by the Wharton School, in collaboration with Accenture, this podcast combines cutting-edge research with real-world case studies to uncover how top companies are using AI to upskill workforces, enhance customer experiences, boost productivity, and streamline operations.  Check it out:  https://link.cohostpodcasting.com/f5e223b4-da0c-4fc8-bbf3-5f24c15f8fd2?d=sxo9xhJN2    Stay Updated: Craig Smith on X:https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) The Power of Precision Medical Forecasting (01:53) Eric Topol's Journey into Digital & AI Medicine (03:27) Using AI to Prevent Aging-Related Diseases (05:25) The Challenge of Health Data Privacy & Ownership (09:05) Genetic Risk to Deep Data Insights (11:20) Personalized Prevention Through Lifestyle & Biomarkers (13:59) Why Anti-Aging Drugs Are Still Years Away (16:18) What are Organ Clocks (19:34) The Longevity Industry's Flawed Use of AI (21:59) Top AI Pioneers Endorse “Super Agers” (24:21) Which Longevity Startups Are Getting It Right? (26:27) Why Topol Refuses to Join Longevity Startups (28:57) Topol's Own Health Data & Lessons Learned (30:25) How Accurate Is AI at Predicting Disease Timing? (31:47) The Truth About Genetic Risk and Cancer Detection (33:33) AI-Driven Cancer Detection: A Smarter Approach (38:51) How Precision Medicine Has Evolved (41:02) The Risky Reality of Anti-Aging Interventions (44:39) Why Healthspan Matters More Than Lifespan

Navigating the intricate landscape of medical technology often involves overcoming substantial challenges, not just in device innovation but also in ensuring successful integration into healthcare systems. One significant hurdle is the adoption of new technologies by general practitioners, who require tools that are both effective and easy to integrate into their existing workflows without the complexities of specialist equipment. In this week's episode, sponsored by Physician Growth Accelerator, we are joined by Cody Simmons, co-founder and CEO of DermaSensor. Cody discusses DermaSensor, a revolutionary device that simplifies skin cancer detection, enabling general practitioners to diagnose with the accuracy of dermatologists. We delve into the story of DermaSensor, from its initial conception to achieving FDA clearance and the challenges faced in bringing this innovative technology to market. What we discuss in the episode: The development of DermaSensor and its impact on simplifying skin cancer detection for non-specialists. The barriers to technology adoption in healthcare, particularly issues around reimbursement and system integration. Strategies employed by DermaSensor to navigate regulatory hurdles and market challenges. Real-world benefits of the device in improving diagnostic accuracy and reducing healthcare inefficiencies. Resources from this episode:  Get the free MedTech Talk Tracks for Action Physician Growth Accelerator DermaSensor Social Media:  Connect with Cody on LinkedIn Connect with Zed on LinkedIn

In this episode of Menopause Mastery, I sit down with Sumit Rai, founder of Cancer Check Labs, to uncover a groundbreaking new approach to cancer screening and prevention. We dive deep into how cancer really develops—years before it's detectable by traditional scans—and why early detection at the cellular level could be the key to saving millions of lives. Sumit shares the powerful story behind his mission, the hidden dangers accelerating cancer rates (including toxins, diet, and lifestyle), and how standard treatments like chemo and surgery often miss the bigger picture. We also explore his revolutionary blood test that can find cancer cells before tumors become visible—and how new technologies like blood filtration could transform cancer care forever. If you're serious about proactive health, longevity, and protecting yourself and your loved ones, this is a must-listen conversation packed with science, hope, and action steps you can take today.  

In the wake of Atlantic editor-in-chief Jeffrey Goldberg's accidental inclusion in senior government officials' Signal group chat discussing war plans, Reid weighs in on how the U.S. government should—and shouldn't—use encrypted messaging apps. He and Aria also discuss AI-powered breakthroughs in cancer detection and medical diagnostics, along with NVIDIA's newly announced Superchip and OpenAI's latest image generation capabilities.  For more info on the podcast and transcripts of all the episodes, visit https://www.possible.fm/podcast/ 

Join us as we review recent articles and news featured in The DIGEST issues #59-61, including cfDNA and incidental detection of cancer in pregnancy, vitamin K2 for nocturnal leg cramps, the danger of as-needed anti-hypertensive medications in the hospital, GLP-1 agonists for alcohol use disorder, short-course (7 vs 14 days) antibiotics for bacteremia, and patient-collected HPV testing for cervical cancer screening. Fill your brain hole with a fully digestible meal! Featuring Laura Glick MD, Nora Taranto (@norataranto), Paul Williams (@paulnwilliamz), and Matt Watto (@doctorwatto).  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction and Overview 02:57 The IDENTIFY study: Non-Invasive Prenatal Testing and Cancer Detection with cfDNA 05:54 Implications of Non-Reportable Results in Prenatal Testing 08:51 Vitamin K2: A New Approach to Managing Nocturnal Leg Cramps 12:07 Practicality and Future of Vitamin K2 in Clinical Practice 23:21 The Dangers of As-Needed Antihypertensives in the hospital 32:21 Exploring GLP-1 Agonists for Alcohol Use Disorder 40:24 Shorter Antibiotic Courses in Sepsis 46:09 Advancements in Patient-Collected HPV Screening for cervical cancer Credits Written and Produced by: Nora Taranto MD, Laura Glick MD, Matthew Watto MD, FACP; Paul Williams MD, FACP Show Notes: Nora Taranto MD Cover Art: Matthew Watto MD, FACP Hosts: Nora Taranto MD, Laura Glick MD, Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Disclosures The Curbsiders report no relevant financial disclosures.  Sponsor: Bombas Head over to Bombas.com/curb and use code curb for 20% off your first purchase. Sponsor: Pretty Litter  Go to PrettyLitter.com/curb to save twenty percent on your FIRST order and get a free cat toy.  Sponsor: Rocket Money  Cancel your unwanted subscriptions and reach your financial goals faster with Rocket Money. Go to RocketMoney.com/CURB today.

Louie Helmecki shares his deeply personal journey through multiple cancer diagnoses, shedding light on the emotional, physical, and medical challenges he faced along the way. From enduring chemotherapy and surgeries to navigating the complexities of cancer recurrence, Louie speaks candidly about the toll of treatment and the resilience required to push forward. He and Freddie Kimmel discuss the critical role of health ownership, the importance of advocating for the right medical care, and the gaps in traditional medicine that often leave patients searching for more holistic solutions. Louie's story is not just about surviving but about reclaiming control over his well-being and redefining what it means to thrive beyond cancer. This conversation also delves into groundbreaking health innovations, including the use of peptides, GLP-1 medications, and lifestyle medicine as tools for recovery and disease prevention. Freddie and Louie explore the latest advancements in cancer detection, weight management, and muscle preservation, emphasizing the importance of a personalized and proactive approach to health. They highlight the growing integration of complementary therapies like red light therapy, IV treatments, and biohacking strategies that support the body's natural healing process. More than just a story of struggle, this episode is a testament to the power of mindset, education, and taking action to build a life beyond illness.Chapters00:00 Introduction to Cancer Journeys05:00 Louie's Cancer Diagnosis and Initial Treatment09:52 Chemotherapy Experiences and Challenges16:01 Surgery and Recovery Insights20:01 Recurrence and New Diagnosis30:00 Navigating Medical Decisions and Expert Opinions35:50 Navigating Cancer Treatment Experiences41:07 The Intersection of Traditional and Complementary Medicine49:01 Innovations in Health and Wellness Practices55:46 Understanding Peptides and Their Impact on Health01:05:59 Exploring Weight Loss Medications01:08:02 The Importance of Comprehensive Health Assessments01:09:55 Navigating Weight Loss Programs Responsibly01:12:03 Innovative Approaches to Health and Wellness01:16:52 Cancer Detection and Preventative Measures01:26:51 Life Lessons from Cancer SurvivalUPGRADE YOUR WELLNESSSilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD (30% off)Code: BEAUTIFULLYBROKENSaga Bands: https://ca.saga.fitness/?ref=titvyccmCode: beautifullybrokenStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED https://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

In today's episode, you'll get to explore the world of early cancer detection with Dr. Azra Raza, a pioneering oncologist and professor of medicine. We discuss the anxiety-inducing issues surrounding current cancer screening methods like mammograms and colonoscopies and examine advanced alternatives such as GRAIL and Cologuard. Dr. Raza also shares her groundbreaking work in detecting "The First Cell" and explores the potential of biomarkers and wearable devices for early detection (check out her fascinating book on this topic for more invaluable information!). In a deeply personal segment, Dr. Raza opens up about her late husband's battle with leukemia and how it shaped her understanding of cancer. We'll also discuss the flaws in the current cancer research model, the financial struggles for innovative scientists, and the urgent need for better funding to accelerate progress. Dr. Azra Raza is the Chan Soon-Shiong Professor of Medicine and Clinical Director of The Edward P. Evans Foundation MDS Center at Columbia University in New York. A practicing oncologist seeing 30–40 cancer patients weekly, she directs a basic cancer research lab with hundreds of original publications in high-profile journals. Her life is dedicated to the prevention of all chronic diseases, including cancer, by early detection. She worked with President Clinton, designing breakthrough developments in science and technology, and with President Joe Biden for the Cancer Moonshot initiative. Her latest book is a national bestseller and has been translated into nine languages. Dr. Raza is now involved in First Cell Therapeutics, developing a specific antibody to target and remove the tumor macrophage hybrid cells that act as The First Cell giving rise to cancer.  Full show notes: https://bengreenfieldlife.com/firstcell Episode Sponsors: Aires Tech: Aires Tech is offering you a 30% discount at airestech.com/ben by using code BEN30. Wild Health: Get 20% off with code BEN at wildhealth.com/ben. FUM: Head to tryfum.com/BEN and use code BEN to get a free gift with your Journey Pack! Vivobarefoot: You can purchase yours today with an exclusive 20% discount by going to vivobarefoot.com/bengreenfield and using code BENG20. MOSH: Head to moshlife.com/BEN to save 20% off plus FREE shipping on either the Best Sellers Trial Pack or the new Plant-Based Trial Pack.See omnystudio.com/listener for privacy information.

On Passion Struck, John is joined by Michael Marquardt, former Chair of the American Cancer Society and CEO of Epi-One, to explore groundbreaking breakthroughs in early cancer detection. The two dive deep into how epigenetic signals in the DNA molecule are revolutionizing how we diagnose cancer, offering hope for earlier and more effective treatments. Don't miss this insightful conversation on the future of cancer detection!His personal experiences with cancer, including the loss of his first wife, have driven his dedication to revolutionizing cancer detection and treatment. The episode shed light on the advancements in cancer research and the critical role of early detection in improving outcomes for cancer patients.Full show notes and resources can be found here: https://passionstruck.com/michael-marquardt-breakthroughs-cancer-detection/SponsorsBabbel is the new way to learn a foreign language. The comprehensive learning system combines effective education methods with state-of-the-art technology! Right now, get SIXTY percent off your Babbel subscription—but only for our listeners, at Babbel dot com slash PASSION.Stop hair loss before it's gone for good. Hims has everything you need to regrow hair. Start your free online visit today at “Hims dot com slash PASSIONSTRUCK.”Quince brings luxury products like Mongolian Cashmere, Italian Leather, Turkish Cotton and Washable Silk to everyone at radically low prices. Go to “Quince dot com slash PASSION” for free shipping on your order and 365-day returns.--► For information about advertisers and promo codes, go to:https://passionstruck.com/deals/JUST $0.99 FOR A LIMITED TIMEOrder a copy of my book, "Passion Struck: Twelve Powerful Principles to Unlock Your Purpose and Ignite Your Most Intentional Life," today!  Recognized as a 2024 must-read by the Next Big Idea Club, the book has won the Business Minds Best Book Award, the Eric Hoffer Award, the International Book Awards for Best Non-Fiction, the 2024 Melanie P. Smith Reader's Choice Contest by Connections eMagazine, and the Non-Fiction Book Awards Gold Medal. Don't miss the opportunity to transform your life with these powerful principles!In this episode, you will learn:The American Cancer Society has funded grants for 50 young researchers who have gone on to win the Nobel Prize.The American Cancer Society focuses on three pillars: research, patient support, and advocacy.Sedentary lifestyle and Western diets are contributing factors to the rise in cancer cases.EpiOne, a biotech startup, is pioneering early cancer detection through epigenetic signals on the DNA molecule.Early detection is crucial in improving cancer survival rates and treatment outcomes.EpiOne's technology can detect cancer signals at stage zero, allowing for early intervention and treatment.All Things Michael Marquardt: https://marquardtglobal.com/Catch More of Passion StruckCan't miss my episode withJulie Fleshman on How PanCAN Is Raising the Pancreatic Cancer Survival RateListen to my interview withDr. Lynn Matrisian on the Frontlines of Pancreatic Cancer – Education, Awareness, and ProgressWatch my episode with Bill Potts on Beat Cancer by Being Your Own Best AdvocateCatch my interview with Dr. Michael Pishvaian on Why Hope Is the Key to Fighting Pancreatic CancerLike this show? Please leave us a review here-- even one sentence helps! Consider including your Twitter or Instagram handle so we can thank you personally!